NASDAQ:JAZZ

Jazz Pharmaceuticals Stock Forecast, Price & News

$173.93
+0.11 (+0.06 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$173.01
$175.53
50-Day Range
$171.49
$186.42
52-Week Range
$107.59
$189.00
Volume327,033 shs
Average Volume489,392 shs
Market Capitalization$9.90 billion
P/E Ratio19.07
Dividend YieldN/A
Beta1.04
30 days | 90 days | 365 days | Advanced Chart
Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Jazz Pharmaceuticals logo

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.57 out of 5 stars

Medical Sector

6th out of 2,215 stocks

Pharmaceutical Preparations Industry

2nd out of 867 stocks

Analyst Opinion: 3.4Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 4.4 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

Is Jazz Pharmaceuticals a buy right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Jazz Pharmaceuticals stock.
View analyst ratings for Jazz Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Jazz Pharmaceuticals?

Wall Street analysts have given Jazz Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Jazz Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Jazz Pharmaceuticals
.

How can I listen to Jazz Pharmaceuticals' earnings call?

Jazz Pharmaceuticals will be holding an earnings conference call on Tuesday, August 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "7187077".

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced its quarterly earnings data on Tuesday, May, 4th. The specialty pharmaceutical company reported $3.92 earnings per share for the quarter, topping the Zacks' consensus estimate of $3.09 by $0.83. The specialty pharmaceutical company earned $607.58 million during the quarter, compared to the consensus estimate of $613.07 million. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 22.95% and a net margin of 21.27%. The firm's revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period last year, the company earned $0.45 EPS.
View Jazz Pharmaceuticals' earnings history
.

How has Jazz Pharmaceuticals' stock been impacted by COVID-19?

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, JAZZ shares have increased by 61.0% and is now trading at $173.93.
View which stocks have been most impacted by COVID-19
.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, July, 15th. The company provided earnings per share (EPS) guidance of $13.400-$14.700 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.050. The company issued revenue guidance of $3.02 billion-$3.18 billion, compared to the consensus revenue estimate of $3.11 billion.

What price target have analysts set for JAZZ?

16 Wall Street analysts have issued 12 month price objectives for Jazz Pharmaceuticals' stock. Their forecasts range from $128.00 to $250.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $201.07 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the following people:
  • Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 57, Pay $2.48M)
  • Mr. Daniel N. Swisher Jr., Pres (Age 58, Pay $1.37M)
  • Ms. Renee D. Gala, Exec. VP & CFO (Age 49, Pay $924.52k)
  • Dr. Robert Iannone M.D., Exec. VP of R&D and Chief Medical Officer (Age 54, Pay $1.05M)
  • Ms. Kim Sablich, Exec. VP & GM of North America (Age 52, Pay $869.48k)
  • Mr. Christopher John Tovey, Exec. VP, COO and MD of Europe & International (Age 56)
  • Ms. Patricia Carr, VP of Fin. & Principal Accounting Officer (Age 50)
  • Dr. Finbar Larkin Ph.D., Sr. VP of Technical Operations (Age 63)
  • Ms. Andrea N. Flynn, VP & Head of Investor Relations
  • Ms. Neena M. Patil J.D., Chief Legal Officer and Sr. VP of Legal & Corp. Affairs (Age 46)

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Jazz Pharmaceuticals' key competitors?

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Oregon Public Employees Retirement Fund (0.06%), State of Alaska Department of Revenue (0.02%), New Mexico Educational Retirement Board (0.02%), Cardinal Capital Management (0.02%), Confluence Investment Management LLC (0.01%) and Stratos Wealth Partners LTD. (0.00%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, James E Flynn, Kenneth W O'keefe, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul L Berns, Paul Treacy and Seamus Mulligan.
View institutional ownership trends for Jazz Pharmaceuticals
.

Which major investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Cardinal Capital Management, Oregon Public Employees Retirement Fund, New Mexico Educational Retirement Board, Confluence Investment Management LLC, and Stratos Wealth Partners LTD.. Company insiders that have bought Jazz Pharmaceuticals stock in the last two years include James E Flynn, and Seamus Mulligan.
View insider buying and selling activity for Jazz Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $173.93.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals has a market capitalization of $9.90 billion and generates $2.36 billion in revenue each year. The specialty pharmaceutical company earns $238.62 million in net income (profit) each year or $10.77 on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals employs 1,940 workers across the globe.

When was Jazz Pharmaceuticals founded?

Jazz Pharmaceuticals was founded in 2003.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

Where are Jazz Pharmaceuticals' headquarters?

Jazz Pharmaceuticals is headquartered at FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at (531) 634-7800 or via email at [email protected]


This page was last updated on 7/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.